Mark Alan Smith

Title: Mark Alan Smith: Innovator in Pharmaceutical Formulations

Introduction

Mark Alan Smith is a notable inventor based in Elkton, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained-release formulations for treating mental health disorders. With a total of 2 patents, his work has the potential to impact the lives of many individuals suffering from schizophrenia and bipolar disorder.

Latest Patents

Smith's latest patents focus on "Sustained release olanzapine formulations." The disclosure is directed to methods of treating schizophrenia or bipolar disorder by subcutaneously administering a sustained-release dosage form of olanzapine, or a pharmaceutically acceptable salt thereof. Additionally, methods of subcutaneously administering olanzapine, or a pharmaceutically acceptable salt thereof, are also described. This innovative approach aims to improve the efficacy and convenience of treatment for patients.

Career Highlights

Mark Alan Smith is currently associated with Teva Pharmaceuticals International GmbH, where he continues to advance his research and development efforts. His work in the pharmaceutical industry has positioned him as a key player in the innovation of drug delivery systems.

Collaborations

Some of his notable coworkers include Ling Chen and Ari Andrew Gershon, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Mark Alan Smith's contributions to pharmaceutical innovations, particularly in sustained-release formulations, highlight his commitment to improving mental health treatment. His work at Teva Pharmaceuticals International GmbH continues to pave the way for advancements in the field.